All In MedTech

Device Trial Radar · NCT04612868

Efficacy and Safety of AEYE-DS Software Device for Automated Detection of Diabetic Retinopathy From Digital Fundus Images

Pivotal Prospective Clinical Trial to Demonstrate the Efficacy and Safety of AEYE-DS Software Device for Automated Diabetic Retinopathy Detection From Digital Fundoscopic Images

Last checked: Nov 20, 2026Latest source record: Aug 1, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingTitle says "pivotal". This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

531

Actual

Start

Oct 16, 2020

Primary completion

Nov 28, 2021

Study completion Dec 26, 2021

Sponsor

Lead sponsor
AEYE Health IncNot on our public-company list
Sponsor type
Industry
First posted
Nov 3, 2020

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated device
Yes
Who can join
All sexes, from 22 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

AEYE-DS is a software device developed to increase compliance with diabetic retinopathy screening by automatically detecting more-than-mild diabetic retinopathy from digital fundus images using Artificial Intelligence (AI)-based software. This study has been designed to validate the safety and efficacy of the device at primary care and other point of care sites.

Conditions

  • Diabetes Mellitus
  • Diabetic Retinopathy

Interventions

  • AEYE Software DeviceDevice

    Eligible participants will undergo the following procedures: * Photographic imaging of each eye using a funduscopy camera device. Images obtained will be sent to the AEYE-DS software for analysis. * Additional photographic and Optical Coherence Tomography (OCT) images will be obtained using a second funduscopy/OCT camera device. Images obtained will be sent to a professional reading center for analysis. * All study subjects will have their pupils dilated using dilation drops.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Sensitivity and Specificity, Based on Two Macula-centered Images (One Image From Each Eye of the Patient)Time frame: 1 day

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Eye Care Institute

    Louisville, Kentucky

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.